EAM
SION

Eventide Asset Management’s Sionna Therapeutics SION Stock Holding History

Eventide Asset Management’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9M Sell
474,981
-170,549
-26% -$6.82M 0.28% 108
2026
Q1 		$25.9M Buy
645,530
+6,485
+1% +$247K 0.43% 81
2025
Q4 		$26.3M Buy
+639,045
New +$24.2M 0.41% 86

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Eventide Asset Management's SION Position: Q2 2026 in Review

Eventide Asset Management reduced its Sionna Therapeutics (SION) stake by 26% in Q2 2026, selling an estimated $6.82M and leaving 474,981 shares worth $20.9M. The position accounts for 0.28% of the portfolio, ranked #108.

Eventide Asset Management first reported a position in SION in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.3M in Q4 2025. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Eventide Asset Management held 474,981 shares of Sionna Therapeutics worth $20.9M as of Q2 2026.
  • Eventide Asset Management sold 170,549 Sionna Therapeutics shares in Q2 2026, an estimated $6.82M.
  • Sionna Therapeutics made up 0.28% of Eventide Asset Management's portfolio in Q2 2026, its #108 holding.
  • Eventide Asset Management first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Eventide Asset Management's Sionna Therapeutics position peaked at $26.3M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.